Literature DB >> 20641121

Long-term outcome of 4 Korean families with hypertrophic cardiomyopathy caused by 4 different mutations.

Jin-Oh Choi1, Cheol-Woong Yu, Jong Chun Nah, Jeong Rang Park, Bok-Soo Lee, Yu Jeong Choi, Byung-Ryul Cho, Sang-Chol Lee, Seung Woo Park, Akinori Kimura, Jeong Euy Park.   

Abstract

BACKGROUND: We sought to describe the long-term outcome of individuals in 4 Korean families with hypertrophic cardiomyopathy (HCM) with known mutations. HYPOTHESIS: Long-term clinical features of familial HCM might be characterized according to the mutation causing HCM.
METHODS: We performed long-term (mean, 13.1 y) clinical evaluations on 46 subjects from 4 Korean families with different mutations.
RESULTS: Myosin light chain 3 gene (MYL3) mutation was associated with late-onset HCM with relatively poor prognosis; 1 sudden cardiac death and 2 cases of heart failure with atrial fibrillation occurred among 12 subjects with this mutation. Myosin binding protein C gene (MYBPC3) mutation was associated with 2 cases of sudden cardiac death and 3 cases of heart failure among 7 affected members. Cardiac troponin I type 3 gene (TNNI3) mutation was associated with 5 deaths related to atrial fibrillation and stroke among 12 mutation-positive members. Myosin heavy chain 7 gene (MYH7) mutation was associated with 11 deaths in 15 affected members.
CONCLUSIONS: The clinical course was quite different for different HCM mutations. Even within the same family, individuals carrying the same mutation differed in disease expression and prognosis. Copyright (c) 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20641121      PMCID: PMC6653452          DOI: 10.1002/clc.20795

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  7 in total

1.  A novel de novo mutation of β-cardiac myosin heavy chain gene found in a twelve-year-old boy with hypertrophic cardiomyopathy.

Authors:  Seigo Okada; Yasuo Suzuki; Takuro Arimura; Akinori Kimura; Hiroko Narumi; Shunji Hasegawa
Journal:  J Genet       Date:  2014-08       Impact factor: 1.166

2.  Aggregate penetrance of genomic variants for actionable disorders in European and African Americans.

Authors:  Pradeep Natarajan; Nina B Gold; Alexander G Bick; Heather McLaughlin; Peter Kraft; Heidi L Rehm; Gina M Peloso; James G Wilson; Adolfo Correa; Jonathan G Seidman; Christine E Seidman; Sekar Kathiresan; Robert C Green
Journal:  Sci Transl Med       Date:  2016-11-09       Impact factor: 17.956

3.  Targeted Next-Generation Sequencing Reveals Hot Spots and Doubly Heterozygous Mutations in Chinese Patients with Familial Cardiomyopathy.

Authors:  Yue Zhao; Yue Feng; Yun-Mei Zhang; Xiao-Xue Ding; Yu-Zhu Song; A-Mei Zhang; Li Liu; Hong Zhang; Jia-Huan Ding; Xue-Shan Xia
Journal:  Biomed Res Int       Date:  2015-06-24       Impact factor: 3.411

Review 4.  Human Induced Pluripotent Stem-Cell-Derived Cardiomyocytes as Models for Genetic Cardiomyopathies.

Authors:  Andreas Brodehl; Hans Ebbinghaus; Marcus-André Deutsch; Jan Gummert; Anna Gärtner; Sandra Ratnavadivel; Hendrik Milting
Journal:  Int J Mol Sci       Date:  2019-09-06       Impact factor: 5.923

5.  A novel Myosin essential light chain mutation causes hypertrophic cardiomyopathy with late onset and low expressivity.

Authors:  Paal Skytt Andersen; Paula Louise Hedley; Stephen P Page; Petros Syrris; Johanna Catharina Moolman-Smook; William John McKenna; Perry Mark Elliott; Michael Christiansen
Journal:  Biochem Res Int       Date:  2012-04-11

6.  Phenotypic diversity identified by cardiac magnetic resonance in a large hypertrophic cardiomyopathy family with a single MYH7 mutation.

Authors:  Jie Wang; Ke Wan; Jiayu Sun; Weihao Li; Hong Liu; Yuchi Han; Yucheng Chen
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

7.  T2-weighted cardiac magnetic resonance image and myocardial biomarker in hypertrophic cardiomyopathy.

Authors:  Shi Chen; Liwei Huang; Qing Zhang; Jie Wang; Yucheng Chen
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.